A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/192 (2006.01) A61K 31/426 (2006.01) A61P 25/02 (2006.01) A61P 25/28 (2006.01)
Patent
CA 2561159
A method for treating demyelinating diseases in a patient in need thereof by treatment with an effective amount of a PPAR delta agonist is disclosed. Demyelinating diseases that may be effectively treated by this method include but are not limited to multiple sclerosis, Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica, adrenoleukodystrophy, Guillian-Barre syndrome and disorders in which myelin forming glial cells are damaged including spinal cord injuries, neuropathies and nerve injury.
La présente invention concerne une technique de traitement de troubles de démyélinisation chez un patient nécessitant ce traitement, avec une quantité efficace d'un agoniste delta PPAR. Parmi les troubles de démyélinisation qui peuvent être efficacement traité par cette technique, citons notamment la sclérose en plaques, la maladie de Charcot Marie, la maladie de Pelizaeus-Merzbacher, l'encéphalomyélite, la neuromyélite optique, l'adrénoleucodystrophie, le syndrome de Guillian-Barre et des troubles dans lesquels des cellules gliales formant la myéline sont dégradées, notamment des blessures de la moelle épinière, des neuropathies et une blessure nerveuse.
Chandross Karen
Khorkova Olga
Lee Lan
Liu Yun
Merrill Jean
Aventis Pharmaceuticals Inc.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Use of peroxisome proliferator activated receptor delta... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of peroxisome proliferator activated receptor delta..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of peroxisome proliferator activated receptor delta... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1989316